GLP-3 RETA (Retatrutide)
Also known as: Retatrutide, LY3437943, GLP-3 RETA
Molecular Overview
Retatrutide (catalogued as GLP-3 RETA) is an investigational triple incretin/glucagon-pathway agonist peptide acting at the GIP, GLP-1, and glucagon receptors. It has been the subject of published pharmacology and clinical-development research in metabolic science.
Mechanistic Background
Simultaneous agonism of GIP, GLP-1, and glucagon receptors engages multiple metabolic-signaling pathways studied in incretin research.
What Researchers Study
Research has focused on receptor pharmacology and metabolic endpoints in translational and clinical-development settings.
Evidence Landscape
Current evidence level: EARLY TRANSLATIONAL. Preclinical evidence does not equate to demonstrated human efficacy.
Research Limitations
This is an investigational agent; content here is educational and not a treatment recommendation. Commercial research preparations may differ from clinical-grade material.
Scientific References
Research Use Only
Molecularix Biolabs provides research materials for legitimate laboratory research. Information in this Research Library is provided for educational and scientific reference purposes and is not medical advice, treatment guidance, or a recommendation for human or veterinary use.